194 related articles for article (PubMed ID: 26836218)
1. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.
Moser HW; Raymond GV; Lu SE; Muenz LR; Moser AB; Xu J; Jones RO; Loes DJ; Melhem ER; Dubey P; Bezman L; Brereton NH; Odone A
Arch Neurol; 2005 Jul; 62(7):1073-80. PubMed ID: 16009761
[TBL] [Abstract][Full Text] [Related]
3. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
[TBL] [Abstract][Full Text] [Related]
4. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
5. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
[TBL] [Abstract][Full Text] [Related]
6. Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.
Deon M; Garcia MP; Sitta A; Barschak AG; Coelho DM; Schimit GO; Pigatto M; Jardim LB; Wajner M; Giugliani R; Vargas CR
Metab Brain Dis; 2008 Mar; 23(1):43-9. PubMed ID: 18026827
[TBL] [Abstract][Full Text] [Related]
7. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the preventive effect of glyceryl trioleate-trierucate ("Lorenzo's oil") therapy in X-linked adrenoleukodystrophy: results of two concurrent trials.
Moser HW; Raymond GV; Koehler W; Sokolowski P; Hanefeld F; Korenke GC; Green A; Loes DJ; Hunneman DH; Jones RO; Lu SE; Uziel G; Giros ML; Roels F
Adv Exp Med Biol; 2003; 544():369-87. PubMed ID: 14713253
[No Abstract] [Full Text] [Related]
9. Effect of erucic acid on platelets in patients with adrenoleukodystrophy.
Kickler TS; Zinkham WH; Moser A; Shankroff J; Borel J; Moser H
Biochem Mol Med; 1996 Apr; 57(2):125-33. PubMed ID: 8733890
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of very long-chain fatty acids levels in X-linked adrenoleukodystrophy, treated with haematopoietic stem cell transplantation and Lorenzo's Oil.
Stradomska TJ; Drabko K; Moszczyńska E; Tylki-Szymańska A
Folia Neuropathol; 2014; 52(2):159-63. PubMed ID: 25118901
[TBL] [Abstract][Full Text] [Related]
11. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
[TBL] [Abstract][Full Text] [Related]
12. Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy.
Duchesne N; Dufour M; Bouchard G; Grondin P; Lemieux B
Can Assoc Radiol J; 1995 Oct; 46(5):386-91. PubMed ID: 7552831
[TBL] [Abstract][Full Text] [Related]
13. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
Moser HW; Moser AB; Hollandsworth K; Brereton NH; Raymond GV
J Mol Neurosci; 2007 Sep; 33(1):105-13. PubMed ID: 17901554
[TBL] [Abstract][Full Text] [Related]
14. Positive effects with Lorenzo's oil.
Siva N
Lancet Neurol; 2005 Sep; 4(9):529. PubMed ID: 16136703
[No Abstract] [Full Text] [Related]
15. Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid.
Sassa T; Wakashima T; Ohno Y; Kihara A
J Lipid Res; 2014 Mar; 55(3):524-30. PubMed ID: 24489110
[TBL] [Abstract][Full Text] [Related]
16. Lorenzo's oil may help to prevent ALD symptoms.
Senior K
Lancet Neurol; 2002 Dec; 1(8):468. PubMed ID: 12849323
[No Abstract] [Full Text] [Related]
17. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
[TBL] [Abstract][Full Text] [Related]
18. Dietary management of X-linked adrenoleukodystrophy.
Moser HW; Borel J
Annu Rev Nutr; 1995; 15():379-97. PubMed ID: 8527226
[TBL] [Abstract][Full Text] [Related]
19. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).
Rasmussen M; Moser AB; Borel J; Khangoora S; Moser HW
Neurochem Res; 1994 Aug; 19(8):1073-82. PubMed ID: 7800117
[TBL] [Abstract][Full Text] [Related]
20. Improvement of clinical and MRI findings in a boy with adrenoleukodystrophy by dietary erucic acid therapy.
Maeda K; Suzuki Y; Yajima S; Asano J; Yamaguchi S; Matsumoto N; Borel J; Moser HW; Orii T
Brain Dev; 1992 Nov; 14(6):409-12. PubMed ID: 1492654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
